The International Trade Commission published notices in the May 30 Federal Register on the following antidumping and countervailing duty (AD/CVD) injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The Commerce Department published notices in the Federal Register May 30 on the following antidumping and countervailing duty (AD/CVD) proceedings (any notices that announce changes to AD/CVD rates, scope, affected firms or effective dates will be detailed in another ITT article):
Suspension of liquidation and antidumping duty cash deposit requirements took effect May 29 for imports of paper file folders from Sri Lanka (A-542-806), after the Commerce Department found dumping in the preliminary determination of its ongoing AD investigation.
The Commerce Department made preliminary affirmative antidumping duty determinations that imports of hard empty capsules from Brazil (A-351-864), China (A-570-184), India (A-533-934) and Vietnam (A-552-847) are being sold in the U.S. at less than fair value. The agency has imposed AD cash deposit requirements on entries of subject merchandise beginning May 29.
The Commerce Department has published the final results of the antidumping duty administrative review on certain oil country tubular goods (OCTG) from South Korea (A-580-870). These final results will be used to set final assessments of AD duties on importers for subject merchandise from six companies under review entered September 2022 through August 2023.
The Commerce Department will impose further antidumping duties on monosodium glutamate imports from Malaysia, suspending liquidation and requiring AD cash deposits for entries over two and a half years earlier, and ending a certification process that had allowed some Malaysian MSG imports to avoid the duties.
The Consumer Product Safety Commission announced the following voluntary recalls May 29:
The Office of the U.S. Trade Representative is seeking comments on whether any act, policy or practice relating to drug prices appears "unreasonable or discriminatory," or appears to have "the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries," it said in a Federal Register notice,
The Office of the U.S. Trade Representative is soliciting comments on whether African countries eligible for the African Growth and Opportunity Act benefits should continue to be eligible for AGOA in 2026. (Congress has to renew AGOA before then, as the whole program expires at the end of September.)
President Donald Trump said at a press conference in the Oval Office that the U.S. would no longer have an economically viable country if higher courts uphold the rulings from the Court of International Trade and a U.S. district court that he doesn't have unbounded power to hike tariffs under an emergency statute.